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Summary.-Serum sialyl transferase (SST) was measured in49female patients with
advanced breast cancer and 60 female controls. The mean SST level was significantly
raised in patients with advanced breast cancer. There was no correlation between
specific sites, or numbers of sites of metastatic disease and SST levels. The patients
with advanced breast cancer were all treated with chemotherapy; in 13/21 responders
there was a significant fall in SST and in 2 responders a significant rise in SST.
The 6 patients who died after one course of chemotherapy had a significantly higher
mean SST than those surviving longer. SST appears to lack sufficient specificity to
be of practical value as a marker of response in patients with breast cancer treated
by chemotherapy, though constant measurement of changes in SST may be of use
in monitoring drug response. Raised SST at the commencement of chemotherapy
may signify poor prognosis.
THE GLYCOSYL TRANSFERASES are a
group ofenzymes involved in glycoprotein
synthesis; they catalyse additionofspecific
monosaccharides to the growing glyco-
protein molecule. There may be altera-
tions in the composition of the various
cell-surface glycoproteins in malignancy
(Van Beek et al., 1]973) and, associated
with this, elevations in the different glyco-
syl transferases found in the sera of
patients with neoplastic disease. Plasma
fucosyl transferase (Khilanani et al., 1 978)
and galactosyl transferase levels (Paone
et al., 1978) have been shown to be
increased in some malignancies. More
particularly, serum and plasma sialyl
transferase has been found to be raised in
patients with breast (Ganzinger & Moser,
1979) and other cancers (Dao et al., 1980;
Ganzinger & Deutsch, 1980). Levels of
this enzyme are reported to reflect t;he
extent of metastatic disease and response
to treatment.
We have measured serum sialyl trans-
ferase (SST) levels in patients with
advanced breast cancer and, as part of a
clinical trial comparing two different
chemotherapy regimens, compared serial
SST levels with the clinical response to
treatment.
METHODS AND MATERIALS
Serumt sialyl transferase assay.-Cytidine
5'-monophosphate sialic acid, sialic-4 (14C)
specific activity 1*68 mCi/mmol was purchased
from New England Nuclear Corp. Ltd. The
desialated acceptor -was prepared from calf
thymus fetuin (Sigma) by removal of the
terminal sialic acid residue.
Analytical-grade anion exchange resin.
Ag-2-X8 (100-200 mesh size) in the chloride
form (Bio-Rad Laboratories) wasx converted
into the hydroxide form by treatment with
IM NaOH, followed by repeated wiashings
with distilled water until pH 7 was achieved.
The scintillation fluid Aquasol wias pur-
chased from Neaw England Nuclear Corp.
Ltd. All samples wiere counted in a PackardSTALY1, TRANSFERASE LEXVELS AN7D CHEAMOTHERAPY
PLD liquid scintillation counter in plastic
vials obtained from Packard.
Preparation of desialated fetuini. Calf thy-
mnus fetuin 1 g Nas dissolved in 25 ml of
distilled water and the terminal sialic acid
esidues removed by the action of 125 ml
IM H2SO4 at 80°C for 1 h. The solution was
chilled. neutralized to pH 7 w-ith 1M NaOH,
and dialysed for 4 h against a 0 5°h NaCl
solution, before finally dialysing overnight
against distilled water. This dialysed solution
was freeze-dried to yield a Ahite pow-der of
desialated fetuin.
Sialyl transferase assay. The complete
assay system contained 25 ,ul serum, 3 ,ul IAi
Hepes buffer (pH 7 0), 10 IAl 0-1M MgC12.
10 ,ul desialated fetuin (20 mg/ml), 5 pu
(1 nmol) Cytidine 5'-monophosphate (14C)
sialic acid, and 60 ,ul distilled wi-ater. This was
incubated for 30 min at 37°C. The product.
desialated fetuin terminally labelled witl
(14C) sialic acid, was isolated using ion-
exchange chromatography and counted in a
liquid-scintillation counter. The mean of
two replicate samples wiasusedinthis analysis.
The interassay variation of 15 determina-
tions and the intra, assay variationi of 40
determinations were both 50.
Patients. Forty-nine patients Awith pro-
gressive metastatic breast canecer. treated
previously by endocrine therapy (ovarian
ablation. androgens. oestrogens or anti-
oestrogens + subsequent hypophysectomy)
but not prior chemotherapy' were treated
wsith Adriamycin (Adr. 70 mg/M2) i.v.
(60 mg/M2 for patients > 60 years) on day I
of a 3-w eekly cycle for 8 cources. followNed by
a regimen of cyclophosphamide (100 mg/M2
p.o., Days 1-14) +methotrexate (30 mg/M2
i.v., Days 1 and 8) + 5-fluorouracil (600
mg/M2 i.v., Days 1 and 8) 4 x weekly until
elapse. They w% ere allocated randomly to
receive either no other treatment or yin-
cristine (1.4 mg/M2) on Days I and 8 during
treatment ith Adr. Before chemotherapy
commenced. patients w-ere assessed clinically
and writh bone scans (including radiographs of
areas of increased uptake), chest radiograph.
full blood count, biochemical screen and
liver scan. A selection of baseline lesions
for serial assessment was obtained. Before
each i.v. injection, a full blood profile (includ-
ing platelets) was done and before each cycle
of chemotherapy patients were examined
and repeat assessment of baseline lesions
made. Every 3 months patients had repeat
radiographs and liver scans if clinically
indicated. Response to treatment wNas assessed
bv UICC criteria (Hayward et al., 1977).
Controls.-Sera were collected from female
volunteers aged 35+ years as part of a
larger study of the aetiology of breast
cancer (Farew^ell et al., 1978). All volunteers
had a clinical examination and mammographv
to exclude breast pathology.
Serum1 collection.-Blood samples from
patients and controls were collected. allowed
to stand for 1 h, centrifuged at 800 g and
the resultant serum wxias stored at -20°C
until assayed. Serum was collected imme-
diately before each cycle of chemotherapy.
Sera from controls were assayed within 1
month of collection, whilst sera from patients
wNere stored for periods of 1 to 24 months
before assay. There were no differences in
baseline enzyme activity between patients
wNhose sera w\as assayed within 1 month of
collection (n= 13). from 1 to 6 months of
collection (n= 16) or for longer than this
period (n=20). In addition, in a sample
assayed on 40 occasions over 2 years, the
coefficient of variation wAas 5%. These results
suggest that, storage at -20°C for up to
2 years does not significantlv alter serum
enzyme activity.
Statistical methods.-Comparisons of group
mean values w-ere tested for significance by
using the t test. The significance ofdifferences
between binary variables was calculated
bv the x2 test for 1 degree of freedom.
RESULTS
Response to chemotherapy
Twelve of 25 (48%) patients responded
to Adr alone and 3/25 (12%) had stable
disease, while 9/14 (38%) responded to the
combination of Adr and vincristine and
6/24 (25%) had stable disease.
Baseline values
The mean baseline serum sialyl trans-
ferase (SST) level in patients with advan-
ced breast cancer was higher than in
controls (Table I). In addition, mean
baseline levels are shown for each categorv
of response to chemotherapy. The 6
patients who died after the first course of
chemotherapy had a mean SST of 406 + 76
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TABLE I.-Response categories and mean
baseline serum sialyl transferase (SST)
estimation
SST (ct/min/
mg protein/bi)
Controls (60) *258 + 41 p
All patients (49) :340+112 J I<
Responders (21) :338 +102
Progressive disease (19) '342 + 84
No change (9) 2>99 + 213
* lean SST + s.d. Figures in parentheses refer
to numbers of patients.
ct/min/mg protein/h, compared to a mean
SST of 331 + 115 for other chemotherapy
patients (P < 0.05). The SST before chemo-
therapy, above or below an arbitrarily
chosen value of 350 ct/min was of some
use in predicting an individual response
category (Table II). Twenty-two of 30
patients with a pretreatment SST of
< 350 ct/min responded to or had stable
disease with chemotherapy, compared to
only 8/19 with a higher baseline level
(X2 4-78, P <0.05).
Table III shows the mean SST accord-
ing to individual disease sites and numbers
of sites involved at the commencement of
chemotherapy. There was no clearrelation-
ship between SST levels and any site, or
numbers of sites, of disease involvement.
Serial values
Measurement of SST at any given time
(e.g. 3-6 weeks) after the initiation of
treatment had no prognostic value. How-
ever, if the pretreatment value for a
particular patient was used as a reference
point, then changes in SST were weakly
related to response. If the SST level was
above the baseline 6 weeks after treat-
ment, the response +no-change rate w%ias
TABLE III.-Baseline SST and sites of
disease at commencement ofchemotherapy.
Figures in brackets refer to number of
patients
Sites of dlisease
Soft tissue only (11)
Skeletal (30)
Hepatic (5)
Visceral (liver and lung) (14)
Non-visceral (35)
One site only (18)
IMIore than one site (31)
SST + s.d.
(et/min/mg prot,ein/li)
338 + 176
:332 + 88
,345 + 79
359 + 88
332+ 119
339 + 139
'340+ 91
8/16 patients: if SST levels had fallen the
response+no-change rate was 18/19
patients (x7=91, P<001). At 6 weeks,
clinical response had been noted in only
6/21 (29%) of patients who eventually
responded to chemotherapy.
If the SST levels were below the pre-
treatment value at both 3 and 6 weeks
after treatment, the response+no-change
rate was 12/12 patients. If SST was
raised both times, the response+no-
change rate was 6/11 patients (X2=6X96,
P < 0005). As no data were available on
the changes in serial SST with time in
patients with untreated metastatic dis-
ease, a significant change in SST was
arbitrarily regarded as >s.d. of controls
(viz. > 41 ct/min/mg protein/h).
Table IV shows the relationship between
the lowest value of SST and response
category. In 13/21 responders there was a
fall in SST in remission, and in 8/21
responders this was a fall of >2 s.d.
(viz. > 82 ct/min/mg protein/h), whilst in
the non-responders there was a fall in 4/13.
and in only 1/13 was this fall > 2 s.d.
These differences are not significant.
TABLE Ii. Baseline SST estimations (ct/min/mgprotein/h) and response categories
Response category
(Total
responders
Responders No clhange + no change)
14 8 22 (73%)
7 1 8 (420o)
21 9 30
Baseline SST
< 350
> 350
Total
Progressive
disease
8 (27oo)
11 (58°,)
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Response category
No Progressive
Response change disease
8
5
6
2
0
1
3
3
1
1
1
3
7
2
0
There was a significant difference (P <
0.025) in the lowest serial value of SST in
responders (252 + 94 ct/min/mg protein/h)
compared to patients with progressive
disease (321 + 94 ct/min/mg protein/h). In
patients responding to chemotherapy,
TABLE V.-Difference between lowest SST
in remission and value at relapse
Difference in SST (ct/min)
No change + < 41
+ >41
- >41
Response category
A
Responder No change
5 2
5 1
1 0
there was no consistent relationship be-
tween lowest SST and time from com-
mencementofchemotherapy, lowestvalues
being found from 3 to 55 weeks after
commencement of chemotherapy. Eleven
responders and 3 patients in the no-
change category have been followed until
relapse. Table V shows the difference
between the lowest SST in remission and
at relapse. There was a significant differ-
ence (P < 0.05) between the lowest SST
in remission (232 + 97) and the level at
relapse (304 + 100). Since there were often
some months between the time of the
lowest SST and the time of relapse, a rise
of SST in remission was of little value in
predicting onset ofrelapse.
DISCUSSION
High SST levels in advanced breast
cancer has been reported by several
groups (Ganzinger & Moser, 1979; Dao
et al., 1980; Kessel & Allen, 1975), and
our results confirm these findings. Unlike
other reports (Dao et al., 1980; Henderson
& Kessel, 1977), there was no clear
relationship between SST levels and sites
or bulk of metastic disease.
It has been shown that surgical removal
of tumour tissue will lead to a fall in SST,
and similarly, after ablative endocrine
therapy, objective regression of disease is
accompanied by a fall in SST (Dao et al.,
1980). In this study it was found that in
11 patients with advanced breast cancer
treated with chemotherapy, significant
falls in SST occurred in all 3 responders
and significant rises in all 4 patients with
progressive disease. Similar results have
been shown by others (Ganzinger & Moser,
1979). Our results also show a fall in SST
is often associated with successful chemo-
therapy, and that a fall may precede
clinical evidence of response. One con-
tradictory finding that emerges from this
study is that although no relationship
between SST and bulk of disease has been
demonstrated, changes in level do reflect
response to treatment and, presumably,
change in tumour burden. All patients in
this study had extensive disease, even if
only one site was involved, and there is
some evidence from animal models that
there is a direct relationship between
sialyl transferase activity and tumour
burden, but only up to a certain threshold,
abovewhichincreasesintumourburdenare
not reflected by increases in SST activity
(Evans et al., 1980). It is possible that the
existence of a similar phenomenon in
human breast cancer may explain this
apparent discrepancy.
Constant and accurate measurement of
changes in SST may be of some use in
monitoring response to chemotherapy,
but both false-negative results (a rise in
SST associated with a response to chemo-
therapy) and false-positive results (a fall
in SST, associated with disease progres-
sion) occur. In view of this lack of speci-
ficity we are investigating the possibility
that a tumour-associated isoenzyme of
sialyl transferase may be a more useful
marker for the follow-up of patients with
breast cancer (Kessel etal., 1981).
TABLE IV.-Lowest SST (ct/min/mg pro-
tein/h) relative to baseline, and response
category
Lowest SST
relative to
baseline
- >82
- >41
No change (±41)
+ >41
+ >82
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